2023, Blinova, E. V., Timoshkin, D. E., Belanov, K. Y., Vasilkina, O. V., Блинова, Екатерина Валериевна

2024, Epishkina, A., Pakina, V., Kutorkina, E., Bogoslovskaya, E., Blinova, E., Блинова, Екатерина Валериевна

2024, Epishkina, A. A., Bogoslovskaya, E. V., Pakina, V. A., Blinova, E. V., Епишкина, Анна Алексеевна, Блинова, Екатерина Валериевна

2023, Makhova, M. V., Shikh, E. V., Strakhov, V. V., Blinova, E. V., Blinov, D. S., Блинова, Екатерина Валериевна

2023, Mirontsev, A. V., Kolesova, L. Yu., Vasil’ev, Yu. L., Blinova, E. V., Миронцев, Артём Владимирович, Блинова, Екатерина Валериевна

2025, Калягина, Н. А., Уденеев, А. М., Блинова, Е. В., Лощенов, М. В., Филькова, А. А., Гармаш, А. А., Гармаш, Александр Александрович, Лощенов, Максим Викторович, Уденеев, Андрей Михайлович, Филькова, Александра Андреевна, Блинова, Екатерина Валериевна, Калягина, Нина Анатольевна

Учебное пособие содержит теоретические и практические аспекты видеофлуоресцентной диагностики и фотодинамической терапии. Приведены концептуальные принципы работы оборудования для флуоресцентной диагностики. В лабораторных работах показаны примеры изготовления жидкостных флуоресцирующих оптических фантомов. Учебное пособие предназначено для студентов, обучающихся по специальности 2.2.12 «Приборы, системы и изделия медицинского назначения», а также студентов, обучающихся по инженерно-физическим специальностям по направлению подготовки 03.03.02, 03.04.02, 03.05.02 «Физика», «Фундаментальная и прикладная физика», 12.03.03, 12.04.03 «Фотоника и оптоинформатика», 12.03.04, 12.04.04 «Биотехнические системы и технологии», 31.05.01 «Лечебное дело» в рамках курса по физике; по укрупнённым группам специальностей: 03 – физические науки, 12 – приборостроение, 31 – лечебное дело.

2026, Osipyants, A. I., Kocharyan, L. S., Lunyov, I. V., Filkova, A. A., Blinova, E. V., Madyarov, Zh. M., Sulimanov, M. A., Осипьянц, Андрей Игоревич, Лунёв, Игорь Вячеславович, Филькова, Александра Андреевна, Блинова, Екатерина Валериевна

2021, Samishina, E., Deryabina, O., Blinov, D., Roshchin, D., Blinova, E., Блинова, Екатерина Валериевна

© 2021 by the authors. Licensee MDPI, Basel, Switzerland.Background: The possible involvement of p53 signaling, FGFR3 expression, and FGFR3 mutation rates in the prediction of the NMIBC anti-PD-L1 treatment response needs to be clarified. The main aim of our study was to explore predictive value of p53 expression, FGFR3 expression, and its gene mutation status for the therapeutic success of anti-PD-L1 treatment in the patient-derived murine model of recurrent high-PD-L1(+) GATA3(-)/CR5/6(-) high-grade and low-grade NMIBC. Methods: twenty lines of patient-derived xenografts (PDXs) of relapsed high-PD-L1(+) double-negative NMIBC were developed, of which 10 lines represented high-grade tumors and the other ones—low-grade bladder cancer. Acceptors of each grade-related branch received specific anti-PD-L1 antibodies. Animals’ survival, tumor-doubling time, and remote metastasis were followed during the post-interventional period. PD-L1, GATA3, CR5/6, and p53 protein expressions in engrafted tumors were assessed by immunohistochemistry. The FGFR3 expression and FGFR3 mutations in codons 248 and 249 were detected by real-time polymerase chain reaction. Results: The expression of p53 protein is an independent factor affecting the animals’ survival time [HR = 0.036, p = 0.031] of anti-PD-L1-treated mice with low-grade high-PD-L1(+) double-negative NMIBC PDX. The FGFR3 expression and FGFR3 mutation rate have no impact on the anti-PD-L1 treatment response in the interventional groups. Conclusions: p53 expression may be considered as a prognostic factor for the anti-PD-L1 treatment efficacy of low-grade high-PD-L1-positive GATA3(-)/CR5/6(-)relapsed noninvasive bladder cancer.

2022, Galichenko, K. A., Blinova, E., Блинова, Екатерина Валериевна

2021, Dudina, M. O., Blinov, D. S., Suslova, I. R., Skachilova, S. Ya., Blinova, E. V., Блинова, Екатерина Валериевна

© 2021 Izdatel'stvo Meditsina. All rights reserved.The antitumor and anti-metastatic effects of aminochromene derivative AKh-554 upon intragastric administration were studied on immunodeficient BALB/c nu/nu female mice with heterotopic human-derived lung adenocarcinoma xenograft model. In the tumor tissue of animals treated with the test compound, the levels of TUBB3, ALK and c-MET/HFG oncomarkers were quantitatively detected and it was found that the drug suppressed the velocity of tumor growth and its size as well as exhibited anti-metastatic activity. AKh-554 produced 3.3-fold increase in tumor carriers survival and induced stable remission in 60% of test mice (p 0.001). The effect might be due to anti-ALK-dependent activation of apoptosis of tumor cells and suppression of cell proliferation. The results were obtained on the tumor system without signs of pharmacoresistance to AX-554, which was confirmed by the lack of dynamics of c-MET/HFG in tumor tissue in all test groups.